We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · November 08, 2021

Pembrolizumab and Entinostat in Patients With Metastatic Uveal Melanoma

Nature Communications


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Communications
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Nat Commun 2021 Aug 27;[EPub Ahead of Print], L Ny, H Jespersen, J Karlsson, S Alsén, S Filges, C All-Eriksson, B Andersson, A Carneiro, H Helgadottir, M Levin, I Ljuslinder, R Olofsson Bagge, VR Sah, U Stierner, A Ståhlberg, G Ullenhag, LM Nilsson, JA Nilsson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading